TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Telix Pharmaceuticals Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026
$10.74+0.05 (+0.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2022 to 2025
Gross margin
53.1%
Operating margin
3.7%
Net margin
-0.9%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +55.6% | – | – | – | |
| Gross profit | +26.9% | – | – | – | |
| Operating income | -46.0% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | -0.7% | |
| Current ratio | – | – | 1.43 | |
| Net debt to EBITDA | – | – | 5.14× | |
| Interest coverage | – | – | 0.7× | |
| Inventory turnover | – | – | 12.4× | |
| Capex to revenue | – | – | 3.2% | |
| Diluted shares | 311M | 311M | 338M |
Cash use needs five years of cash flow figures
Telix Pharmaceuticals does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$7.13M
- Cash generatingOperating cash flow above zero-$17.29M
- Return on assets improvedROA up on the prior year12.1% → -0.8%
- Earnings backed by cashOperating cash flow above net income-$17.29M vs -$7.13M
- Less leverageLong-term debt to assets fell36.3% → 33.7%
- Better liquidityCurrent ratio rose2.78 → 1.43
- No dilutionShare count did not rise345M → 338M
- Gross margin improvedGross margin up on the prior year65.08% → 53.05%
- More efficientAsset turnover rose1.86 → 0.85